SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea · Delayed Price · Currency is KRW

87,200

+5,000 (6.08%)

Last updated: Jun 24, 2026, 2:31 PM KST

-4.07% (1Y)

Market Cap	6.44T -9.5%
Revenue (ttm)	790.25B +36.7%
Net Income	348.81B +38.9%
EPS	4,452.45 +38.8%
Shares Out	78.31M
PE Ratio	18.46
Forward PE	19.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161,243
Open	82,000
Previous Close	82,200
Day's Range	81,500 - 87,400
52-Week Range	81,000 - 144,100
Beta	0.70
Analysts	Buy
Price Target	134,818.18 (+54.61%)
Earnings Date	Aug 7, 2026

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilep... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1993

Employees 246

Stock Exchange Korea Stock Exchange

Ticker Symbol 326030

Full Company Profile

Financial Performance

In 2025, SK Biopharmaceuticals's revenue was 706.74 billion, an increase of 29.06% compared to the previous year's 547.60 billion. Earnings were 266.95 billion, an increase of 10.89%.

Financial Statements

Analyst Summary

According to 10 analysts, the average rating for 326030 stock is "Buy." The 12-month stock price target is ₩134,818, which is an increase of 54.61% from the latest price.

Price Target

₩134,818

(54.61% upside)

Analyst Consensus: Buy

Stock Forecasts